Aytu BioPharma Q3 fiscal 2024 positive adjusted EBITDA $0.4M; ADHD revenue up 49% YoY

AYTU BIOPHARMA, INC

2025-Q3 EPS reported -$2.04 vs consensus -$0.23 ▼ miss (-769.6%)

Q3 net loss $2.9M ($0.52/sh) vs $7.2M loss prior year; positive adjusted EBITDA $0.4M.
ADHD Portfolio net revenue up 49% to $12.3M; Rx gross margin improved to 74%.
Consumer Health net revenue down 56% to $4.0M; wind-down continues as planned.
TTM companywide adjusted EBITDA positive $15.4M; Rx Business TTM adjusted EBITDA $17.1M.
Cash $19.8M; manufacturing transition expected to improve margins.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

AYTU BIOPHARMA, INC reported fiscal 2024 third quarter results: revenue $18.0 million, net income $2.9 million, EPS $0.52 per share.

Period: fiscal 2024 third quarter
Revenue: $18.0 million
Net income: $2.9 million
EPS: $0.52 per share
Result: reported results

Exact text from the filing

on commercializing novel therapeutics, today announced financial and operational results for the fiscal 2024 third quarter. Q3 2024 Highlights ● Consolidated net revenue was $18.0 million versus $22.7 million in the prior year period and reflects the Company’s continued planned wind down of its Consumer Health Segment. ● ADHD Portfolio (Adzenys XR-ODT® and

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

AYTU BIOPHARMA, INC filing history →

Source: SEC EDGAR

accession 0001437749-24-017058

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.